NHS to provide Pfizer's Voxelotor to treat sickle cell disease [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
The latest development comes after the National Institute for Health and Care Excellence (NICE) granted approval for the treatment in patients aged 12 years and above. The decision will benefit up to 4,000 patients in England with the genetic blood disorder. Voxelotor, which will be available in tablet form for daily intake, can reduce the frequency of blood transfusions and hospital visits. It offers a new treatment option for those who have had severe reactions to treatment or prefer not to undergo blood transfusions. The NHS will immediately fund Voxelotor through the Innovative Medicines Fund, ensuring rapid access for patients. Clinical trials have demonstrated that Voxelotor could improve anaemia and reduce the necessity for repeated blood transfusions. In trials, 51% of participants treated with Voxelotor experienced an increase in haemoglobin levels, reducing their symptoms and enhancing their overall quality of life. 74% of patients taking the drug reported a s
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Moderna wins patent case in Europe against Pfizer, BioNTech over COVID shot [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Pfizer Stock: Rebound Has Started (Technical Analysis) [Seeking Alpha]Seeking Alpha
- Active Pharmaceutical Ingredient Market Worth $238.3 billion | MarketsandMarkets™ [Yahoo! Finance]Yahoo! Finance
- Pfizer: Potential Double-Digit Upside Combined With High Dividend Yield [Seeking Alpha]Seeking Alpha
- 2 Top Growth Stocks Down 24% and 50% to Buy With $100 [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 5/1/24 - Beat
PFE
Sec Filings
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- 5/9/24 - Form S-8
- PFE's page on the SEC website